Comparison

AbbVie Inc. (ABBV) vs BRISTOL MYERS SQUIBB CO (BMY)

The same filed metrics for both companies, side by side.

What each names as a risk in its own annual report, how each is priced against its own history, and the tracked managers whose latest 13F reports a position in both.

Financials

ABBV

AbbVie Inc.

Drug Manufacturers—General

Revenue, FY25: $61.16B
Net income: $4.23B
Operating cash flow: $19.03B
Free cash flow: $17.82B
Net margin: 6.91%
Operating margin: 24.65%
Gross margin: 70.24%

BMY

BRISTOL MYERS SQUIBB CO

Drug Manufacturers—General

Revenue, FY25: $48.19B
Net income: $7.05B
Operating cash flow: $14.16B
Free cash flow: $12.85B
Net margin: 14.64%
Operating margin: -
Gross margin: 71.08%

Head-to-head

Filed growth, quality and valuation, read against each company’s own history rather than against the other side.

Metric	ABBV	BMY
Revenue growth, latest filed year	+8.57%	−0.22%
Piotroski F-score	8 of 9	8 of 9
P/E against its own history	54.65% above	22.05% below

What each says it is exposed to

From Item 1A of each company’s most recent 10-K.

ABBV

Reimbursement
Goodwill impairment
Litigation
Product recalls
FDA approval
Supply chain

And 16 more.

BMY

Reimbursement
FDA approval
Litigation
Tax
Cybersecurity
Tariffs

And 19 more.

Tracked managers holding both

Joel Greenblatt Gotham Asset Management 0.06% · 0.12%
Dodge & Cox Dodge & Cox 0.00% · 0.00%

Updated Sep 3, 2026 · the newer of the two companies' filings